<DOC>
	<DOCNO>NCT02241785</DOCNO>
	<brief_summary>The primary objective study determine efficacy natalizumab ( Tysabri , BG00002 ) participant relapse form multiple sclerosis ( MS ) fail Gilenya BRACET ( Betaseron , Rebif , Avonex , Copaxone , Extavia , Tecfidera ) measure proportion participant evidence disease activity ( NEDA ) Year 1 . The secondary objective study population : Change total T1 hypointense total T2 hyperintense lesion volume ; Proportion participant NEDA Year 2 ; Evaluation impact natalizumab annualized relapse rate ( ARR ) ; Change Multiple Sclerosis Impact Scale-29 ( MSIS-29 ) physical impact score .</brief_summary>
	<brief_title>Natalizumab Efficacy Switch Participants With Relapsing Multiple Sclerosis ( MS ) After Failure Other Therapies</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Subjects childbearing potential must practice effective contraception Day 1 willing able continue contraception duration study . Must document diagnosis relapse MS ( McDonald 2010 Criteria [ Polman 2011 ] ) Screening . Must treat Gilenya BRACET least 6 month prior Screening interruption treatment . Prior treatment natalizumab allow ; however , must minimum 1 year since last natalizumab infusion Screening visit study , discontinuation natalizumab past due intolerance , antinatalizumab antibody , efficacy loss . Must disease activity 12 month prior Screening Gilenya BRACET ( define least 1 Gd+ lesion OR least 2 new T2 lesion ( compare MRI do within 12 month screen ) OR clinical relapse , EDSS progression 1 point ) Must EDSS score 0 5.5 inclusive Screening . Must lymphocyte count document low limit normal ( LLN ) day first Tysabri infusion . If lymphocyte return LLN day first Tysabri infusion ( day 0 ) , subject screen fail . The subject screen fail eligible undergo Rescreening ; additional Rescreening consider , please contact study medical monitor . Key History positive test result Screening human immunodeficiency virus ( HIV ) . History positive test result Screening hepatitis C virus antibody ( HCV Ab ) current hepatitis B infection ( define positive hepatitis B surface antigen [ HBsAg ] and/or hepatitis core antibody [ HBcAb ] ) . Prior treatment natalizumab ( either commercially clinical study ) within 1 year Day 1 . Contraindications treatment natalizumab describe Prescribing Information participate country . Known allergy natalizumab ingredient , know antinatalizumab antibody positive . Diagnosis primary progressive MS , secondary progressive MS , and/or progressiverelapsing MS. An MS relapse occur within 30 day prior Day 1 and/or subject stabilize previous relapse prior Day 1 . Known active malignancy ( subject cutaneous basal cell carcinoma completely excise prior study entry remain eligible ) . History severe opportunistic infection ( include PML ) clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease , determine Investigator Clinically severe active infection within 1 month prior Screening . Females breastfeeding , pregnant , plan become pregnant ; woman postmenopausal surgically sterile unwilling practice contraception ; woman positive pregnancy test result Day 1 . Prior history immunosuppressant use ( e.g. , mitoxantrone , azathioprine , methotrexate , cyclophosphamide , mycophenolate , cladribine , rituximab ) last 12 month prior Screening . Prior history alemtuzumab use point past . NOTE : Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>